N. Chalumeau, Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases, Rheumatology Medicine, vol.93, issue.1, pp.1-10

. Value, Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group, Haematologica, vol.97, issue.4, pp.529-562, 2012.

R. Stasi, S. Amadori, A. Newland, and D. Provan, Infliximab chimeric antitumor necrosis factor-?? monoclonal antibody as potential treatment for myelodysplastic syndromes, Leukemia & Lymphoma, vol.19, issue.4, pp.509-525, 2005.
DOI : 10.1111/j.1365-2257.1997.tb00007.x

S. Kimura, J. Kuroda, T. Akaogi, H. Hayashi, Y. Kobayashi et al., Trisomy 8 Involved in Myelodysplastic Syndromes as a Risk Factor for Intestinal Ulcers and Thrombosis ??? Beh??et's Syndrome, Leukemia & Lymphoma, vol.55, issue.1-2, pp.115-136, 2001.
DOI : 10.1016/S0145-2126(98)00097-6

N. Pipitone, L. Masini, and C. Salvarani, A case of arthritis and vasculitis associated with the refractory anemia with excess of blasts syndrome resistant to glucocorticoid treatment that responded favorably to TNF-alpha blockade, Clinical and experimental rheumatology, vol.24, issue.2, pp.31-35, 2006.

T. Toyonaga, H. Nakase, M. Matsuura, N. Minami, S. Yamada et al., Refractoriness of Intestinal Beh??et's Disease with Myelodysplastic Syndrome Involving Trisomy 8 to Medical Therapies - Our Case Experience and Review of the Literature, Digestion, vol.88, issue.4, pp.217-238, 2013.
DOI : 10.1159/000355341

J. Fraison, A. Mekinian, E. Grignano, J. Kahn, J. Arlet et al., Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia, Leukemia Research, vol.43, pp.13-20, 2016.
DOI : 10.1016/j.leukres.2016.02.005

URL : https://hal.archives-ouvertes.fr/hal-01278608

J. Fine and . Gr, A Proportional Hazards Model for the Subdistribution of a Competing Risk, Journal of the American Statistical Association, vol.69, issue.446, pp.496-509, 1999.
DOI : 10.1093/biomet/69.1.239

A. Ustwani, O. Francis, J. Wallace, P. Ambrus, J. et al., Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. Leukemia research Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study, Arthritis Care Res, vol.35, issue.128, pp.35-6631188

H. Enright and W. Miller, Autoimmune Phenomena in Patients with Myelodysplastic Syndromes, Leukemia & Lymphoma, vol.24, issue.5-6, pp.5-6483, 1997.
DOI : 10.1016/S0190-9622(09)80090-X

G. Pazzola, F. Muratore, N. Pipitone, and C. Salvarani, Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study Biologics in vasculitides: Where do we stand, where do we go from now, Leukemia. Presse Med, vol.1644, issue.166 2, pp.162-166, 2002.

S. Sanges, S. Riviere, A. Mekinian, T. Martin, L. Quellec et al., Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature, Autoimmunity Reviews, vol.16, issue.4, pp.377-84, 2017.
DOI : 10.1016/j.autrev.2017.02.008

R. Komrokji, A. Kulasekararaj, A. Ali, N. Kordasti, S. Bart-smith et al., Autoimmune diseases and myelodysplastic syndromes, American Journal of Hematology, vol.99, issue.5, pp.280-283, 2016.
DOI : 10.3324/haematol.2012.083345

L. Sullivan, M. Sekeres, N. Shrestha, J. Maciejewski, R. Tiu et al., Epidemiology and risk factors for infections in myelodysplastic syndromes. Transplant infectious disease : an official journal of the Transplantation Society, pp.652-659, 2013.